

Atty Dkt. No.: UCAL-082CON USSN: 09/938,853

IN THE CLAIMS

Please amend claims 17 and 24 as shown below.

1. - 16. (Previously Canceled)

- MAR 0 1 2004
- 17. (Currently Amended) A method for treating heart failure in a subject, comprising:
- a) administering an angiotensin II (AT₁) receptor inhibitor to said subject for a first period beginning at about the time of a myocardial infarction;
- b) reducing administration of said angiotensin II (AT₁) receptor inhibitor after said initial period; and
- c) administering a <u>human</u> growth hormone during a second period beginning after said reducing administration of said AT₁ receptor inhibitor.
- 18. (Previously Presented) The method of claim 17, wherein said first period has a duration of about 10 to 12 weeks.
- 19. (Previously Presented) The method of claim 17, wherein the AT₁ receptor inhibitor is administered at least once daily.
- 20. (Previously Presented) The method of claim 17, wherein AT₁ receptor inhibitor administration is discontinued following said first period.
- 21. (Previously Presented) The method of claim 17, wherein said AT₁ receptor inhibitor comprises losartan.
- 22. (Previously Presented) The method of claim 17, wherein said growth hormone is administered for about two weeks to about three months.
- 23. (Previously Presented) The method of claim 17, wherein said reducing of AT₁ receptor inhibitor allows for a favorable physiologic hypertrophic effect from said growth hormone.

Atty Dkt. No.: UCAL-082CON

USSN: 09/938,853

A method of treating heart failure in a subject, comprising; 24. (Currently Amended)

administering an angiotensin II (AT₁) receptor inhibitor to said subject over a first period a) beginning about the time of an ischemic event, and said first period continuing for a sufficient amount of time to substantially permit favorable left ventricular remodeling or limit unfavorable ventricular remodeling;

- decreasing said administering of AT₁ receptor inhibitor at a time approximately after said b) ventricular remodeling; and
- administering a human growth hormone to said subject during a second period beginning c) at a time approximately after said ventricular remodeling.
- The method of claim 24, wherein administering said AT₁ receptor 25. (Previously Presented) inhibitor is discontinued at about the time administering said growth hormone begins.
- 26. (Previously Presented) The method of claim 24, wherein the angiotensin II (AT_1) receptor inhibitor is administered at least once daily.
- The method of claim 24, wherein administration of said AT₁ 27. (Previously Presented) receptor inhibitor is discontinued at about the time administering said growth hormone begins.
- 28. (Previously Presented) The method of claim 24, wherein said administration of said AT₁ receptor inhibitor following said ventricular remodeling is decreased prior to the end of said first period.
- 29. (Previously Presented) The method of claim 24, wherein said AT₁ receptor inhibitor comprises losartan.
- 30. (Previously Presented) The method of claim 24, wherein said growth hormone is human growth hormone.
- 31. (Previously Presented) The method of claim 24, wherein said AT₁ receptor inhibitor is administered beginning within seven days of said ischemic event.

Atty Dkt. No.: UCAL-082CON

USSN: 09/938,853

32. (Previously Presented) The method of claim 24, wherein said AT₁ receptor inhibitor is administered for about 8 to about 12 weeks.

- 33. (Previously Presented) The method of claim 24, wherein said AT₁ receptor inhibitor is administered for about 10 weeks.
- 34. (Previously Presented) The method of claim 24, wherein said growth hormone is administered for about two weeks to about three months.
- 35. (Previously Presented) The method of claim 24, wherein a second administration of a composition comprising AT₁ receptor inhibitor is administered for a time following said growth hormone administration.
- 36. (Previously Presented) The method of claim 35, wherein growth hormone is administered following said second administration of AT₁ receptor inhibitor.
- 37. (Previously Presented) The method of claim 24, wherein decreasing said administering of AT₁ receptor inhibitor allows for a favorable physiologic hypertrophic effect from said growth hormone.